Scholarlink

<p>IgA nephropathy (IgAN) is the most prevalent glomerular disease worldwide, frequently resulting in end-stage kidney disease (ESKD). The identification of reliable non-invasive biomarkers for disease monitoring and prognosis is warranted, despite the fact that renal biopsy is the gold standard for diagnosis. Therefore, the objective of the current investigation is to assess the potential of serum Gd-IgA1 as a biomarker for IgA nephropathy in a tertiary care center in South India. This study examined the serum levels of galactose-deficient IgA1 (Gd-IgA1) in patients with histologically confirmed IgAN (n = 135), non-IgA glomerulopathies (n = 55), and healthy controls (n = 85). Serum Gd-IgA1 concentrations were determined using ELISA, and their associations with clinical and histopathological parameters were analyzed. The study revealed a marked variation in serum Gd-IgA1 levels across the three patient categories of IgA nephropathy. In comparison to healthy controls and non-IgA nephropathy patients, the mean circulating Gd-IgA1 levels were significantly elevated in IgA nephropathy patients. Correlation analysis demonstrated a positive correlation between serum creatinine, eGFR, and the Gd-IgA1/C3 ratio and Gd-IgA1 levels. Nevertheless, no substantial correlation was observed between Gd-IgA1 levels and other clinical parameters. ROC curve analysis of serum Gd-IgA1 levels showed a moderate ability to distinguish between IgA nephropathy and non-IgA nephropathy group.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Utility of the Serum Gd-IgA1 to C3 Ratio in Diagnosing Patients with IgA Nephropathy

  • 期刊论文

  • 发表日期：

    2025年12月3日

查看全文
  • Ravi Tej Madipalli,
  • Kaushik Puranam,
  • Sonu Manuel,
  • Vijay Kumar Kutala,
  • Sree Bhushan Raju

摘要

IgA nephropathy (IgAN) is the most prevalent glomerular disease worldwide, frequently resulting in end-stage kidney disease (ESKD). The identification of reliable non-invasive biomarkers for disease monitoring and prognosis is warranted, despite the fact that renal biopsy is the gold standard for diagnosis. Therefore, the objective of the current investigation is to assess the potential of serum Gd-IgA1 as a biomarker for IgA nephropathy in a tertiary care center in South India. This study examined the serum levels of galactose-deficient IgA1 (Gd-IgA1) in patients with histologically confirmed IgAN (n = 135), non-IgA glomerulopathies (n = 55), and healthy controls (n = 85). Serum Gd-IgA1 concentrations were determined using ELISA, and their associations with clinical and histopathological parameters were analyzed. The study revealed a marked variation in serum Gd-IgA1 levels across the three patient categories of IgA nephropathy. In comparison to healthy controls and non-IgA nephropathy patients, the mean circulating Gd-IgA1 levels were significantly elevated in IgA nephropathy patients. Correlation analysis demonstrated a positive correlation between serum creatinine, eGFR, and the Gd-IgA1/C3 ratio and Gd-IgA1 levels. Nevertheless, no substantial correlation was observed between Gd-IgA1 levels and other clinical parameters. ROC curve analysis of serum Gd-IgA1 levels showed a moderate ability to distinguish between IgA nephropathy and non-IgA nephropathy group.